rAAVen Therapeutics

Executive Summary

rAAVen Therapeutics, a private Swedish biotech founded in 2021, specializes in engineering adeno-associated virus (AAV) capsids for precision gene therapy delivery. Leveraging high-throughput molecular cloning and next-generation sequencing, the company designs viral vectors optimized to target specific tissues and cell populations, addressing a broad range of disorders. While still in early preclinical stages, rAAVen's proprietary capsid engineering platform has the potential to overcome key limitations of current gene therapies, such as off-target effects and immunogenicity. The company operates out of Stockholm and benefits from Sweden's strong life sciences ecosystem. Although no funding or partnership details are publicly disclosed, its focused approach on next-generation AAV vectors positions it as a potential player in the gene therapy space, pending further validation.

Upcoming Catalysts (preview)

• TBDPreclinical Proof-of-Concept Data for Lead Capsid Variant40% success
• TBDSeries A Financing Round35% success
• TBDResearch Collaboration or Licensing Deal30% success